abstract |
The present invention relates to GLP-1 and / or glucagon receptor agonists (eg, oxintomodulin peptide analogs), pharmaceutically acceptable salts thereof, formulations containing them, and diabetes and / or obesity or related disorders or Regarding its use for treating disorders. [Selection diagram] None |